Syndax Pharmaceuticals, Inc.

NASDAQ:SNDX

19.1 (USD) • At close September 6, 2024
Bedrijfsnaam Syndax Pharmaceuticals, Inc.
Symbool SNDX
Munteenheid USD
Prijs 19.1
Beurswaarde 1,625,341,240
Dividendpercentage 0%
52-weken bereik 11.215 - 25.34
Industrie Biotechnology
Sector Healthcare
CEO Mr. Michael A. Metzger M.B.A.
Website https://www.syndax.com

An error occurred while fetching data.

Over Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant

Vergelijkbare Aandelen

Keros Therapeutics, Inc. logo

Keros Therapeutics, Inc.

KROS

52.51 USD

REGENXBIO Inc. logo

REGENXBIO Inc.

RGNX

11.48 USD

National Research Corporation logo

National Research Corporation

NRC

21.71 USD

Mirum Pharmaceuticals, Inc. logo

Mirum Pharmaceuticals, Inc.

MIRM

41.12 USD

Sana Biotechnology, Inc. logo

Sana Biotechnology, Inc.

SANA

5.04 USD

Morphic Holding, Inc. logo

Morphic Holding, Inc.

MORF

56.99 USD

Enanta Pharmaceuticals, Inc. logo

Enanta Pharmaceuticals, Inc.

ENTA

11.54 USD

Aclaris Therapeutics, Inc. logo

Aclaris Therapeutics, Inc.

ACRS

1.17 USD

Treace Medical Concepts, Inc. logo

Treace Medical Concepts, Inc.

TMCI

5.33 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)